Cellinfinity Bio

Cellinfinity Bio is a pre-clinical company focused on CRISPR-based engineering of immune cells, such as T cells and natural killer (NK) cells, to generate chimeric antigen receptors (CARs) targeted against multiple malignancies including solid tumours. By leveraging proprietary methods for directed evolution of cells, Cellinfinity identifies genetic modifications and CAR constructs that substantially improve engineered T-cell and NK-cell activities against solid tumours. Cellinfinity develops both first-in-class and best-in-class cell therapy products with the goal to benefit diverse patient populations with unmet medical needs.